Quantitating therapeutic disruption of tumor blood flow with intravital video microscopy

Arthur M Iga1, Sandip Sarkar, Kevin M Sales

  • 1GI and Hepatobiliary Research Unit, Academic Division of Surgical and Interventional Sciences, University College London and Department of Surgery, Royal Free Hampstead NHS Trust Hospital, London, United Kingdom.

Cancer Research
|December 21, 2006
PubMed

Insights

Vascular-disrupting agents (VDAs) are anticancer drugs that target tumor blood vessels. Intravital video microscopy offers real-time insights into how these agents affect tumor circulation, aiding preclinical assessments.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Vascular-disrupting agents (VDAs) are a class of anticancer drugs designed to eliminate tumor cells by disrupting tumor blood circulation.
  • Preclinical assessment of VDAs is crucial for evaluating their pharmacodynamic endpoints and therapeutic windows.
  • Understanding the real-time effects of VDAs on tumor microcirculation is essential for optimizing cancer therapy.

Purpose of the Study:

  • To review the application of intravital video microscopy in assessing tumor vascular response to VDAs.
  • To highlight the potential of intravital microscopy for quantitative, real-time analysis of VDA effects on tumor microcirculation.

Main Methods:

  • Review of existing literature on intravital video microscopy and VDAs.
  • Analysis of how intravital microscopy can measure specific variables related to tumor vascular function.
  • Focus on real-time data acquisition for understanding VDA mechanisms.

Main Results:

  • Intravital video microscopy enables quantitative measurement of tumor vascular responses to VDAs.
  • This technique provides real-time information on the dynamic effects of VDAs on tumor microcirculation.
  • The data obtained can inform preclinical assessments and therapeutic strategies.

Conclusions:

  • Intravital video microscopy is a valuable tool for studying the pharmacodynamics of VDAs.
  • Real-time monitoring of tumor microcirculation enhances the understanding of VDA efficacy.
  • This approach supports the preclinical evaluation and development of VDA-based cancer treatments.

Related Concept Videos